In 2018, Stubljar et al. summarized H. pylori vaccine development and stated that the development of an effective H. pylori vaccine needs to determine the antigens and adjuvants, and selecting an appropriate adjuvant is as important as selecting a suitable antigen. Thus, the discovery of suitable adjuvants is of vital importance.
Although, only a few vaccine adjuvants are currently approved by the FDA, including aluminum, AS04, AS03, MF59, CpG 1018, and AS01B. The new vaccine adjuvant discovery line offers additional possibilities, such as PPR agonists, iNKT cell agonists, polysaccharides, nanoparticles, mucosal adjuvants, saponins, and cytokines. Ace Therapeutics, as a company specializing in H. pylori research, offers professional H. pylori vaccine adjuvants discovery services. We use ligand scanning technology to identify potent adjuvant candidates of PPR agonists and we explore iNKT cell agonists as candidate adjuvants for H. pylori vaccines. In particular, we tend to focus on the collection of adjuvants that can be used in oral vaccines against H. pylori.
Learn more: h pylori subunit vaccines